Agenus (NASDAQ:AGEN) Price Target Raised to $4.00

Agenus (NASDAQ:AGEN) had its price objective lifted by Robert W. Baird from $3.00 to $4.00 in a report published on Tuesday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on the stock. StockNews.com raised shares of Agenus from a “sell” rating to a “hold” rating in a report on Friday, March 21st. B. Riley reissued a “buy” rating on shares of Agenus in a report on Monday, April 21st. Finally, HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Wednesday, April 30th. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $9.00.

Agenus Stock Performance

Shares of AGEN stock opened at $3.38 on Tuesday. Agenus has a one year low of $1.38 and a one year high of $19.69. The company’s 50-day simple moving average is $2.21 and its 200-day simple moving average is $2.91. The stock has a market capitalization of $71.56 million, a price-to-earnings ratio of -0.30 and a beta of 1.48.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.58. The company had revenue of $24.07 million for the quarter, compared to the consensus estimate of $26.38 million. As a group, research analysts forecast that Agenus will post -12.55 EPS for the current year.

Institutional Investors Weigh In On Agenus

Several large investors have recently made changes to their positions in the company. B. Riley Financial Inc. acquired a new stake in shares of Agenus in the fourth quarter valued at approximately $2,074,000. Siren L.L.C. acquired a new stake in shares of Agenus in the first quarter valued at approximately $752,000. Gilead Sciences Inc. acquired a new stake in shares of Agenus in the fourth quarter valued at approximately $635,000. Northern Trust Corp increased its stake in shares of Agenus by 14.8% in the fourth quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company’s stock valued at $572,000 after purchasing an additional 26,870 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Agenus by 34.0% in the fourth quarter. Bank of America Corp DE now owns 107,123 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 27,157 shares during the period. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.